An IL28B Genotype-Based Clinical Prediction Model for Treatment of Chronic Hepatitis C 英文参考文献.docVIP

下载本文档

7
0
约4.46万字
约 9页
2017-05-11 发布于上海
举报
版权申诉

An IL28B Genotype-Based Clinical Prediction Model for Treatment of Chronic Hepatitis C 英文参考文献.doc

1、本文档共9页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

An IL28B Genotype-Based Clinical Prediction Model for Treatment of Chronic Hepatitis C 英文参考文献

AnIL28BGenotype-BasedClinicalPredictionModelfor TreatmentofChronicHepatitisC ThomasR.O’Brien1*,JamesE.Everhart2,TimothyR.Morgan3,4,AnnaS.Lok5,RaymondT.Chung6, YongwuShao7,MitchellL.Shiffman8,MyhanhDotrang9,JohnJ.Sninsky10,HerbertL.Bonkovsky11,12, RuthM.Pfeiffer1,andtheHALT-CTrialGroup 1DivisionofCancerEpidemiologyandGenetics,NationalCancerInstitute,NationalInstitutesofHealth,DepartmentofHealthandHumanServices,Bethesda,Maryland, UnitedStatesofAmerica,2DivisionofDigestiveDiseasesandNutrition,NationalInstituteofDiabetesandDigestiveandKidneyDiseases,NationalInstitutesofHealth, DepartmentofHealthandHumanServices,Bethesda,Maryland,UnitedStatesofAmerica,3DivisionofGastroenterology,UniversityofCaliforniaIrvine,Irvine,California, UnitedStatesofAmerica,4GastroenterologyService,VALongBeachHealthcareSystem,LongBeach,California,UnitedStatesofAmerica,5DivisionofGastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan, United States of America, 6Gastrointestinal Unit, Medical Services, Massachusetts General Hospital, DepartmentofMedicine,HarvardMedicalSchool,Boston,Massachusetts,UnitedStatesofAmerica,7InformationManagementServices,SilverSpring,Maryland,United StatesofAmerica,8LiverInstituteofVirginia,BonSecoursHealthSystem,NewportNews,Virginia,UnitedStatesofAmerica,9CSC,Rockville,Maryland,UnitedStatesof America, 10Celera Corporation, Alameda, California, United States of America, 11Departments of Medicine and Molecular Structural Biology and The Liver-Biliary- PancreaticCenter,UniversityofConnecticutHealthCenter,Farmington,Connecticut,UnitedStatesofAmerica,12CarolinasMedicalCenter,Charlotte,NorthCarolina, UnitedStatesofAmerica Abstract Background: Genetic variation in IL28B and other factors are associated with sustained virological response (SVR) after pegylated-interferon/ribavirintreatmentforchronichepatitisC(CHC).UsingdatafromtheHALT-CTrial,wedevelopeda modeltopredictapatient’sprobabilityofSVRbasedonIL28Bgenotypeandclinicalvariables. Methods:HALT-Cenroll